Literature DB >> 1826672

Reduced stimulation of helper T cells by Ki-ras transformed cells.

D J Maudsley1, W J Bateman, A G Morris.   

Abstract

A number of viral genes and cellular oncogenes inhibit major histocompatibility complex (MHC) antigen expression at the cell surface. In the case of inhibition of class I MHC antigens by viral genes this results in a reduced recognition by antigen-specific cytotoxic T cells. The activated Ki-ras cellular oncogene carried by the Ki-murine sarcoma virus (Ki-MuSV) in contrast inhibits class II MHC (or Ia) antigen expression on transformed cells. We have studied how transformation with Ki-ras affects recognition by alloreactive helper T cells. We found that the Ki-ras inhibition of class II MHC antigen expression led to greatly reduced stimulation of alloreactive T cells to proliferate and to secrete interferon-gamma (IFN-gamma). These findings support our hypothesis that the ability of an oncogene to reduce class II MHC antigen expression is crucial to its ability to produce tumour cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826672      PMCID: PMC1384496     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  37 in total

1.  CTL recognition of adenovirus-transformed cells infected with influenza virus: lysis by anti-influenza CTL parallels adenovirus-12-induced suppression of class I MHC molecules.

Authors:  J W Yewdell; J R Bennink; K B Eager; R P Ricciardi
Journal:  Virology       Date:  1988-01       Impact factor: 3.616

2.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.

Authors:  K Forrester; C Almoguera; K Han; W E Grizzle; M Perucho
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

3.  Department of Biological Sciences, University of Warwick, Coventry, CV47AL, England.

Authors:  G J Atkins; M D Johnston; L M Westmacott; D C Burke
Journal:  J Gen Virol       Date:  1974-12       Impact factor: 3.891

4.  Immunology. Naked or peptide-clothed MHC?

Authors:  D H Margulies
Journal:  Nature       Date:  1989-11-09       Impact factor: 49.962

5.  Aberrant expression of Ia-like antigens on tumor cells of regressing but not of progressing Rous sarcomas.

Authors:  P C Powell; K Hála; G Wick
Journal:  Eur J Immunol       Date:  1987-05       Impact factor: 5.532

6.  Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas.

Authors:  M Prat; S Bretti; M Amedeo; S Landolfo; P M Comoglio
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

7.  Qualitative and quantitative studies of antigen-presenting cell function by using I-A-expressing L cells.

Authors:  R I Lechler; M A Norcross; R N Germain
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

8.  Role of interferon-gamma in T-cell responses to Semliki Forest virus-infected murine brain cells.

Authors:  P T Tomkins; G A Ward; A G Morris
Journal:  Immunology       Date:  1988-03       Impact factor: 7.397

9.  c-myc down-regulates class I HLA expression in human melanomas.

Authors:  R Versteeg; I A Noordermeer; M Krüse-Wolters; D J Ruiter; P I Schrier
Journal:  EMBO J       Date:  1988-04       Impact factor: 11.598

10.  Kirsten murine sarcoma virus abolishes interferon gamma-induced class II but not class I major histocompatibility antigen expression in a murine fibroblast line.

Authors:  D J Maudsley; A G Morris
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  8 in total

1.  Modulation of MHC antigen expression by viruses and oncogenes.

Authors:  D J Maudsley; J D Pound
Journal:  Immunol Today       Date:  1991-12

Review 2.  Modulation of major histocompatibility complex antigen expression by viral infection.

Authors:  C R Rinaldo
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

Review 3.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

4.  Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss.

Authors:  Lee Ann Jolly; Nicole Massoll; Aime T Franco
Journal:  J Clin Cell Immunol       Date:  2016-09-16

5.  An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy.

Authors:  Neeraj Lal; Andrew D Beggs; Benjamin E Willcox; Gary W Middleton
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

6.  Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles.

Authors:  Matthew S Strand; Bradley A Krasnick; Hua Pan; Xiuli Zhang; Ye Bi; Candace Brooks; Christopher Wetzel; Narendra Sankpal; Timothy Fleming; S Peter Goedegebuure; David G DeNardo; William E Gillanders; William G Hawkins; Samuel A Wickline; Ryan C Fields
Journal:  Oncotarget       Date:  2019-07-30

7.  KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.

Authors:  Neeraj Lal; Brian S White; Ghaleb Goussous; Oliver Pickles; Mike J Mason; Andrew D Beggs; Philippe Taniere; Benjamin E Willcox; Justin Guinney; Gary W Middleton
Journal:  Clin Cancer Res       Date:  2017-10-23       Impact factor: 12.531

Review 8.  KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment.

Authors:  Daniel Zeitouni; Yuliya Pylayeva-Gupta; Channing J Der; Kirsten L Bryant
Journal:  Cancers (Basel)       Date:  2016-04-18       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.